



RECEIVED

AUG 23 2001

TECH CENTER 1600/2900  
PENDING CLAIMS

RECEIVED

AUG 21 2001

OFFICE OF PETITIONS

RECEIVED

AUG 22 2001

TECH CENTER 1600/2900

Re: U.S. Patent Application No. 09/492,697  
Filed January 27, 2000  
Atty. Docket No.: 3495.0111-11

C2/24

38. A retroviral vector comprising an endonuclease site selected from the group consisting of HO endonuclease and Group I intron encoded endonuclease sites.
39. The retroviral vector of claim 38, wherein said endonuclease site is a Group I intron encoded endonuclease site.
40. The retroviral vector of claim 39, wherein said endonuclease site is selected from the group consisting of Class I I-endonuclease sites, Class II I-endonuclease sites, Class III I-endonuclease sites, Class IV I-endonuclease sites, and Class V I-endonuclease sites.
41. The retroviral vector of claim 40, wherein said endonuclease site is a Class I I-endonuclease site.
42. The retroviral vector of claim 41, wherein said endonuclease site is selected from the group consisting of I-SceI, I-SceIV, I-CsmI, and I-PanI sites.
43. The retroviral vector of claim 42, wherein said endonuclease site is an I-SceI site.
44. The retroviral vector of any of claims 38-43, wherein said retroviral vector is a Moloney Murine Leukemia Virus vector.
45. A recombinant mammalian chromosome comprising a Group I intron encoded endonuclease site.
46. The recombinant chromosome of claim 45, wherein said endonuclease site is selected from the group consisting of Class I I-endonuclease sites, Class II I-endonuclease sites, Class III I-endonuclease sites, Class IV I-endonuclease sites, and Class V I-endonuclease sites.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

Copy

47. The recombinant chromosome of claim 46, wherein said endonuclease site is a Class I I-endonuclease site.
48. The recombinant chromosome of claim 47, wherein said Class I I-endonuclease site is selected from I-SceI, I-SceIV, I-CsmI, and I-PanI sites.
49. The recombinant chromosome of claim 48, wherein said Class I I-endonuclease site is an I-SceI site.
50. The recombinant chromosome of any of claims 45-49, wherein said chromosome is a murine chromosome.
51. The recombinant chromosome of claim 50, wherein said chromosome is a mouse chromosome.
52. A recombinant mammalian cell comprising the recombinant chromosome of claim 45.
53. The recombinant cell of claim 52, wherein said endonuclease site is selected from the group consisting of Class I I-endonuclease sites, Class II I-endonuclease sites, Class III I-endonuclease sites, Class IV I-endonuclease sites, and Class V I-endonuclease sites.
54. The recombinant cell of claim 53, wherein said endonuclease site is a Class I I-endonuclease site.
55. The recombinant cell of claim 54, wherein said Class I I-endonuclease site is selected from I-SceI, I-SceIV, I-CsmI, and I-PanI sites.
56. The recombinant cell of claim 55, wherein said Class I I-endonuclease site is an I-SceI site.

*Wag*

57. The recombinant cell of any of claims 52-56, wherein said cell is a murine cell.
58. The recombinant cell of claim 57, wherein said murine cell is a mouse cell.
59. The recombinant cell of claim 57, wherein said murine cell is a murine stem cell.
60. The recombinant cell of claim 59, wherein said murine stem cell is a mouse stem

cell.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000